CYP7A1 and fatty liver disease: There is growing interest in understanding the role of BA metabolism in chronic disease with a specific interest in Cyp7a1, the rate‐limiting enzyme for BA synthesis, as a potential target for therapeutic interventions to prevent hepatic steatosis (Chiang, 2013).